Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Levels of endocrine-disrupting chemicals are associated with changes in the peri-pubertal epigenome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Role of fasting duration and weekday in incretin and glucose regulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Secretion of parathyroid hormone may be coupled to insulin secretion in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Blocking of efflux transporters in rats improves translational validation of brain radioligands

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Kjell Oberg
  • Eric Krenning
  • Anders Sundin
  • Lisa Bodei
  • Mark Kidd
  • Margot Tesselaar
  • Valentina Ambrosini
  • Richard P Baum
  • Matthew Kulke
  • Marianne Pavel
  • Jaroslaw Cwikla
  • Ignat Drozdov
  • Massimo Falconi
  • Nicola Fazio
  • Andrea Frilling
  • Robert Jensen
  • Klaus Koopmans
  • Tiny Korse
  • Dik Kwekkeboom
  • Helmut Maecke
  • Giovanni Paganelli
  • Ramon Salazar
  • Stefano Severi
  • Jonathan Strosberg
  • Vikas Prasad
  • Aldo Scarpa
  • Ashley Grossman
  • Annemeik Walenkamp
  • Mauro Cives
  • Irene Virgolini
  • Andreas Kjaer
  • Irvin M Modlin
View graph of relations

The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

Original languageEnglish
JournalEndocrine Connections
Volume5
Issue number5
Pages (from-to)174-87
Number of pages14
ISSN2049-3614
DOIs
Publication statusPublished - Sep 2016

    Research areas

  • Journal Article

ID: 49874676